Back to discover
Disease

Thyroid gland papillary carcinoma

Active therapeutic pipeline
Also known as papillary cancer of the thyroid, papillary cancer of the thyroid gland, papillary cancer of thyroid, papillary cancer of thyroid gland+9 more

papillary cancer of the thyroid, papillary cancer of the thyroid gland, papillary cancer of thyroid, papillary cancer of thyroid gland, papillary carcinoma of the thyroid, papillary carcinoma of the thyroid gland, papillary carcinoma of thyroid, papillary carcinoma of thyroid gland, papillary thyroid cancer, papillary thyroid carcinoma, papillary thyroid gland carcinoma, thyroid gland papillary cancer, thyroid papillary carcinoma.

12
Clinical trials
12
Associated genes
4
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones6View
Results posted 3
Results expected 3
Activity timeline6

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Sorafenibapproved

Approval — Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcino… (2006)

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
12
All trials
5
Active
0
Late-stage
6
Completed
Recently completed

An Open-Label, Non-Randomized, Dose Escalation, Single-Center, Investigator-Initiated Trial to Determine the Safety, Dosimetry, and Preliminary Effectiveness of 177Lu-DOTA-EB-FAPI in Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With Progressive Disease After Tyrosine Kinase Inhibitors Treatment

Phase 1 · Completed · The First Affiliated Hospital of Xiamen University

Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study

Phase 2 · Completed · Academic and Community Cancer Research United

Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers

Phase 2 · Completed · Academic and Community Cancer Research United

Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers

Phase 2 · Completed · National Cancer Institute (NCI)

Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements

Phase 2 · Completed · National Cancer Institute (NCI)

Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy

Phase 2 · Completed · National Cancer Institute (NCI)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2006emaApproval — Sorafenib· Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

NRG10.49NTRK30.40CCDC60.40EML40.39NCOA40.38GPC30.38ERC10.37STRN0.37TFG0.37TPR0.37TRIM240.37TRIM330.37

Disease biology

4 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Pro-neuregulin-1, membrane-bound isoformvia NRG10.49NT-3 growth factor receptorvia NTRK30.40Coiled-coil domain-containing protein 6via CCDC60.40Echinoderm microtubule-associated protein-like 4via EML40.39

Reference

Authoritative identity, definition & identifiers.

Synonyms

papillary cancer of the thyroid, papillary cancer of the thyroid gland, papillary cancer of thyroid, papillary cancer of thyroid gland, papillary carcinoma of the thyroid, papillary carcinoma of the thyroid gland, papillary carcinoma of thyroid, papillary carcinoma of thyroid gland, papillary thyroid cancer, papillary thyroid carcinoma, papillary thyroid gland carcinoma, thyroid gland papillary cancer, thyroid papillary carcinoma

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.